Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
First targeted therapy for severe childhood epilepsy nears FDA approval

First targeted therapy for severe childhood epilepsy nears FDA approval

New Capabilities

Relutrigine could become the first FDA-approved treatment for SCN2A and SCN8A developmental epileptic encephalopathies, with a decision expected by September 2026

March 30th, 2026: FDA accepts application with priority review

Overview

Children with SCN2A and SCN8A developmental and epileptic encephalopathies have never had a drug designed for their condition. They cycle through four or more medications, none approved for their specific genetic disorder, while their seizures persist and their development regresses. Now, for the first time, a targeted therapy has cleared every major hurdle on its way to the U.S. Food and Drug Administration (FDA): the agency accepted Praxis Precision Medicines' application for relutrigine and granted it priority review, setting a decision deadline of September 27, 2026.

The clinical evidence behind the application was strong enough that an independent safety committee told researchers to stop the trial early—the drug was already working. In the registrational study, patients on relutrigine experienced a 53% greater reduction in seizures compared to placebo, and the number of seizure-free days rose by 66%. If approved, relutrigine would be the first precision therapy for these conditions, potentially transforming outcomes for thousands of children worldwide whose families have had no targeted option until now.

Why it matters

Thousands of children with devastating genetic epilepsy may soon have the first drug ever designed specifically for their condition.

Play on this story Voices Debate Predict

Key Indicators

53%
Placebo-adjusted seizure reduction
In the registrational study, relutrigine reduced countable motor seizures by 53% more than placebo over 16 weeks.
0
Current FDA-approved targeted therapies
No targeted treatments exist today for SCN2A or SCN8A developmental and epileptic encephalopathies.
~90%
Seizure reduction at 11 months
Patients in the open-label extension phase saw approximately 90% seizure reduction after 11 months on the drug.
Sep 27, 2026
FDA target decision date
The agency will decide whether to approve relutrigine by this date under its six-month priority review timeline.
$7.7B
Praxis market capitalization
The company's valuation reflects investor confidence across four late-stage clinical programs.

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Marcio Souza
Marcio Souza
Leading company through transition to commercial-stage
 Steven Petrou
Steven Petrou
Leading R&D across four clinical-stage programs

Organizations Involved

Praxis Precision Medicines
Praxis Precision Medicines
Biopharmaceutical Company
Transitioning from clinical-stage to commercial-stage with two NDA submissions under FDA review

A Boston-based precision neuroscience company developing targeted therapies for neurological disorders caused by imbalances in neuronal excitation and inhibition.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulatory agency
Reviewing relutrigine NDA under priority review

The federal agency responsible for evaluating and approving new drugs, including granting expedited pathways for therapies addressing serious conditions with unmet medical needs.
FamilieSCN2A Foundation
FamilieSCN2A Foundation
Patient Advocacy Organization
Leading advocacy for SCN2A disorder research and treatment access

A nonprofit dedicated to funding research and supporting families affected by SCN2A-related disorders, working directly with the FDA on patient-centered drug development.

Timeline

  1. FDA accepts application with priority review

    Regulatory

    The FDA accepted the relutrigine NDA and granted priority review, compressing the review timeline from ten months to six. Decision expected by September 27, 2026.

  2. Praxis submits new drug application to the FDA

    Regulatory

    Praxis filed its first NDA, seeking approval for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies.

  3. Results presented at American Epilepsy Society meeting

    Scientific

    Full EMBOLD data presented to the epilepsy research community at the AES Annual Meeting.

  4. Trial stopped early—drug already working

    Clinical Trial

    An independent Data Monitoring Committee recommended halting the EMBOLD registrational study early after relutrigine demonstrated clear efficacy: 53% placebo-adjusted seizure reduction and 66% increase in seizure-free days.

  5. FDA grants Breakthrough Therapy designation

    Regulatory

    The FDA recognized relutrigine's potential to offer substantial improvement over existing therapies for SCN2A and SCN8A epileptic encephalopathies.

  6. EMBOLD Cohort 1 shows 46% seizure reduction

    Clinical Trial

    First cohort of 16 patients showed a 46% placebo-adjusted reduction in motor seizures, with five patients achieving seizure-free status versus none on placebo.

  7. Praxis Precision Medicines founded

    Corporate

    Kiran Reddy, David Goldstein, and Steven Petrou founded the company to translate genetic epilepsy research into precision therapies.

Scenarios

Predict which scenario wins. Contrarian picks score more — points lock in when the scenario resolves.

Log in to predict. Track your picks, climb the leaderboard. Log in Sign Up
1

FDA approves relutrigine on or before September 27, 2026

The most likely outcome given the regulatory signals. Relutrigine received every expedited designation the FDA offers, the pivotal trial was stopped early because the drug was already demonstrating clear benefit, and no patients experienced drug-related serious adverse events. Approval would make relutrigine the first targeted therapy for SCN2A and SCN8A epileptic encephalopathies and entitle Praxis to a Rare Pediatric Disease Priority Review Voucher worth an estimated $100 to $350 million. Praxis has $1.5 billion in cash to fund a commercial launch.

Discussed by: Wall Street analysts covering Praxis (consensus 'Strong Buy' with $572 price target); rare disease regulatory experts noting the convergence of Breakthrough Therapy designation, early trial stoppage for efficacy, and clean safety profile
Consensus —
2

FDA requests additional data, delaying approval by months

The FDA could issue a Complete Response Letter requesting longer-term safety data, additional subgroup analyses, or manufacturing information before granting approval. The EMBOLD study enrolled 51 patients in its registrational cohort—small by conventional standards, though typical for rare pediatric conditions. An FDA advisory committee meeting, if convened, could surface questions about durability of effect or the drug's profile in younger children. This would delay but likely not prevent eventual approval given the strength of the data.

Discussed by: Biotech industry analysts who note that small trial sizes in rare diseases sometimes prompt FDA requests for additional safety or efficacy follow-up
Consensus —
3

Approval expands to broader epilepsy population

Praxis is already running the EMERALD trial testing relutrigine in a broader population of patients with developmental and epileptic encephalopathies, regardless of genetic subtype. If both the initial SCN2A/SCN8A approval and the EMERALD trial succeed, relutrigine's addressable patient population would expand substantially. This would transform it from a niche rare disease therapy into a broader epilepsy treatment, significantly increasing its commercial potential and the number of patients who benefit.

Discussed by: Praxis leadership and neurology researchers tracking the ongoing EMERALD Phase 3 trial in developmental and epileptic encephalopathies beyond SCN2A/SCN8A
Consensus —

Historical Context

Epidiolex approval for Dravet and Lennox-Gastaut syndromes (2018)

June 2018

What Happened

GW Pharmaceuticals won FDA approval for Epidiolex (cannabidiol), the first plant-derived cannabinoid medicine and the first drug approved specifically for Dravet syndrome and Lennox-Gastaut syndrome—severe childhood epilepsies that, like SCN2A and SCN8A encephalopathies, had limited targeted treatment options. The approval followed a Breakthrough Therapy designation and Priority Review.

Outcome

Short Term

Epidiolex provided the first FDA-approved option for two devastating epilepsy syndromes, generating over $500 million in annual revenue within two years.

Long Term

The approval opened a pathway for precision therapies targeting specific epilepsy subtypes and demonstrated that the FDA would support accelerated review for drugs addressing severe childhood neurological conditions with strong clinical evidence.

Why It's Relevant Today

Relutrigine follows a nearly identical regulatory trajectory—Breakthrough Therapy, Orphan Drug, and Priority Review designations for a severe pediatric epilepsy with no approved targeted therapy. Epidiolex's commercial success demonstrated robust demand among families desperate for effective treatment options.

Zolgensma approval for spinal muscular atrophy (2019)

May 2019

What Happened

Novartis (through its AveXis subsidiary) won FDA approval for Zolgensma, a one-time gene therapy for spinal muscular atrophy (SMA) in children under two years old. The drug earned Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations—the same trio relutrigine holds. Priced at $2.1 million per patient, it became the most expensive drug in the world.

Outcome

Short Term

Zolgensma generated over $1.3 billion in its first full year of sales. AveXis received a Rare Pediatric Disease Priority Review Voucher, which Novartis sold to Takeda for $350 million.

Long Term

The approval validated the commercial model for precision therapies in ultra-rare pediatric diseases and demonstrated the value of Priority Review Vouchers as a financial incentive for rare disease drug development.

Why It's Relevant Today

Praxis holds the same Rare Pediatric Disease designation and could receive a Priority Review Voucher worth hundreds of millions upon approval. Zolgensma's trajectory illustrates how targeted therapies for rare childhood conditions can generate substantial revenue despite small patient populations—a model Praxis is positioning relutrigine to follow.

Brineura approval for CLN2 disease (2017)

April 2017

What Happened

BioMarin won FDA approval for Brineura (cerliponase alfa), the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2 disease), a fatal neurodegenerative condition that strikes children around age two and causes seizures, loss of motor function, and death by early adolescence. The approval was based on a study of just 24 patients—even smaller than relutrigine's EMBOLD trial.

Outcome

Short Term

Brineura was approved based on a single-arm study with a historical comparator, demonstrating the FDA's willingness to accept unconventional trial designs for devastating pediatric diseases. BioMarin received a Priority Review Voucher it sold to Gilead for $125 million.

Long Term

The approval established precedent that small trials in ultra-rare pediatric diseases can support approval when the unmet need is severe and the treatment effect is clear.

Why It's Relevant Today

Relutrigine's EMBOLD trial enrolled 51 patients—small by conventional standards but larger than Brineura's pivotal study. The Brineura precedent suggests the FDA is prepared to approve based on limited patient numbers when the disease is severe, no alternatives exist, and the clinical signal is strong.

Sources

(6)
+1
GlobeNewsWire MarketScreener Praxis Precision Medicines Investor Relations BioSpace NeurologyLive GlobeNewsWire